Anhar Zahrani, Shaimaa Salaam, Sahar Alsifri, Amjad Alghamdi, Mohammed Zamil
{"title":"羟氯喹致系统性红斑狼疮患者皮肤色素沉着1例。","authors":"Anhar Zahrani, Shaimaa Salaam, Sahar Alsifri, Amjad Alghamdi, Mohammed Zamil","doi":"10.5455/medarh.2025.79.67-70","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.</p><p><strong>Objective: </strong>This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.</p><p><strong>Case presentation: </strong>In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.</p><p><strong>Conclusion: </strong>Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.</p>","PeriodicalId":94135,"journal":{"name":"Medical archives (Sarajevo, Bosnia and Herzegovina)","volume":"79 1","pages":"67-70"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045584/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.\",\"authors\":\"Anhar Zahrani, Shaimaa Salaam, Sahar Alsifri, Amjad Alghamdi, Mohammed Zamil\",\"doi\":\"10.5455/medarh.2025.79.67-70\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.</p><p><strong>Objective: </strong>This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.</p><p><strong>Case presentation: </strong>In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.</p><p><strong>Conclusion: </strong>Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.</p>\",\"PeriodicalId\":94135,\"journal\":{\"name\":\"Medical archives (Sarajevo, Bosnia and Herzegovina)\",\"volume\":\"79 1\",\"pages\":\"67-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045584/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical archives (Sarajevo, Bosnia and Herzegovina)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/medarh.2025.79.67-70\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical archives (Sarajevo, Bosnia and Herzegovina)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/medarh.2025.79.67-70","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.
Background: Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.
Objective: This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.
Case presentation: In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.
Conclusion: Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
